Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency

被引:63
作者
Dvorak, Christopher C. [1 ]
Hassan, Amel [2 ]
Slatter, Mary A. [3 ]
Hoenig, Manfred [4 ]
Lankester, Arjan C. [5 ]
Buckley, Rebecca H. [6 ,7 ]
Pulsipher, Michael A. [8 ]
Davis, Jeffrey H. [9 ]
Guengoer, Tayfun [10 ]
Gabriel, Melissa [11 ]
Bleesing, Jacob H. [12 ]
Bunin, Nancy [13 ]
Sedlacek, Petr [14 ]
Connell, James A. [15 ]
Crawford, David F. [16 ]
Notarangelo, Luigi D. [17 ,18 ]
Pai, Sung-Yun [19 ,20 ]
Hassid, Jake [1 ]
Veys, Paul [2 ]
Gennery, Andrew R. [3 ]
Cowan, Morton J. [1 ]
机构
[1] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Allergy Immunol & Blood & Marrow Trans, San Francisco, CA 94143 USA
[2] UCL Inst Child Hlth, Mol Immunol Unit, Ctr Immunodeficiency, London, England
[3] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Univ Med Ctr, Dept Pediat, Ulm, Germany
[5] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RA Leiden, Netherlands
[6] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27706 USA
[7] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27706 USA
[8] Univ Utah, Sch Med, Div Hematol & Hematol Malignancies, Primary Childrens Hosp,Hunstman Canc Inst, Salt Lake City, UT USA
[9] British Columbia Childrens Hosp, Hematol Oncol BMT Program, Vancouver, WA USA
[10] Univ Childrens Hosp, Stem Cell Transplantat Dept, Zurich, Switzerland
[11] Childrens Hosp Westmead, Dept Oncol, Sydney, NSW, Australia
[12] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[13] Childrens Hosp Philadelphia, Dept Pediat, Div Oncol, Philadelphia, PA 19104 USA
[14] Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic
[15] Univ Michigan, Div Pediat Hematol Oncol, Ann Arbor, MI 48109 USA
[16] Univ Oklahoma, Dept Pediat, Oklahoma City, OK USA
[17] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA
[18] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA
[19] Dana Farber Canc Inst, Boston Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA
[20] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
关键词
Severe combined immunodeficiency; hematopoietic cell transplantation; sibling donors; unrelated donors; umbilical cord blood; conditioning; serotherapy; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; COMBINED IMMUNE-DEFICIENCY; CORD BLOOD; B-CELLS; RECONSTITUTION; CHILDREN; ENGRAFTMENT; EXPERIENCE; CLEARANCE;
D O I
10.1016/j.jaci.2014.06.021
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Patients with severe combined immunodeficiency disease who have matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditioning chemotherapy. Objective: We sought to determine whether the results of HCT without chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSDs. Methods: We performed a multicenter survey of severe combined immunodeficiency transplantation centers in North America, Europe, and Australia to compile retrospective data on patients who have undergone unconditioned HCT from either URDs (n = 37) or MSDs (n = 66). Results: Most patients undergoing URD HCT (92%) achieved donor T-cell engraftment compared with 97% for those with MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% and 60%, respectively) compared with MSD recipients (92% and 89%, respectively; P < .01 for both). URD recipients who received pre-HCT serotherapy had similar 5-year overall survival (100%) to MSD recipients. The incidences of grade II to IV acute and chronic graft-versus-host disease were higher in URD (50% and 39%, respectively) compared with MSD (22% and 5%, respectively) recipients (P < .01 for both). In the surviving patients there was no difference in T-cell reconstitution at the last follow-up between the URD and MSD recipients; however, MSD recipients were more likely to achieve B-cell reconstitution (72% vs 17%, P < .001). Conclusion: Unconditioned URD HCT achieves excellent rates of donor T-cell engraftment similar to that seen in MSD recipients, and reconstitution rates are adequate. However, only a minority will have myeloid and B-cell reconstitution, and attention must be paid to graft-versus-host disease prophylaxis. This approach might be safer in children ineligible for intense regimens to spare the potential complications of chemotherapy.
引用
收藏
页码:935 / U263
页数:24
相关论文
共 37 条
[1]   Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects [J].
Bacigalupo, A .
BONE MARROW TRANSPLANTATION, 2005, 35 (03) :225-231
[2]   Differential roles of STAT1α at and STAT1β in fludarabine-induced cell cycle arrest and apoptosis in human B cells [J].
Baran-Marszak, F ;
Feuillard, J ;
Najjar, I ;
Le Clorennec, C ;
Béchet, JM ;
Dusanter-Fourt, I ;
Bornkamm, GW ;
Raphaël, M ;
Fagard, R .
BLOOD, 2004, 104 (08) :2475-2483
[3]   Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency [J].
Bhattacharya, A ;
Slatter, MA ;
Chapman, CE ;
Barge, D ;
Jackson, A ;
Flood, TJ ;
Abinun, M ;
Cant, AJ ;
Gennery, AR .
BONE MARROW TRANSPLANTATION, 2005, 36 (04) :295-299
[4]   Post-Transplantation B Cell Function in Different Molecular Types of SCID [J].
Buckley, Rebecca H. ;
Win, Chan M. ;
Moser, Barry K. ;
Parrott, Roberta E. ;
Sajaroff, Elisa ;
Sarzotti-Kelsoe, Marcella .
JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (01) :96-110
[5]   Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency [J].
Buckley, RH ;
Schiff, SE ;
Schiff, RI ;
Markert, ML ;
Williams, LW ;
Roberts, JL ;
Myers, LA ;
Ward, FE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (07) :508-516
[6]   Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype [J].
Cavazzana-Calvo, Marina ;
Carlier, Frederique ;
Le Deist, Francoise ;
Morillon, Estelle ;
Taupin, Pierre ;
Gautier, David ;
Radford-Weiss, Isabelle ;
Caillat-Zucman, Sophie ;
Neven, Benedicte ;
Blanche, Stephane ;
Cheynier, Remi ;
Fischer, Alain ;
Hacein-Bey-Abina, Salima .
BLOOD, 2007, 109 (10) :4575-4581
[7]   Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant [J].
Chiesa, Robert ;
Gilmour, Kimberly ;
Qasim, Waseem ;
Adams, Stuart ;
Worth, Austen J. J. ;
Zhan, Hong ;
Montiel-Equihua, Claudia A. ;
Derniame, Sophie ;
Cale, Catherine ;
Rao, Kanchan ;
Hiwarkar, Prashant ;
Hough, Rachel ;
Saudemont, Aurore ;
Fahrenkrog, Cristian S. ;
Goulden, Nick ;
Amrolia, Persis J. ;
Veys, Paul .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (05) :656-666
[8]   Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches [J].
Czechowicz, Agnieszka ;
Kraft, Daniel ;
Weissman, Irving L. ;
Bhattacharya, Deepta .
SCIENCE, 2007, 318 (5854) :1296-1299
[9]   Hematopoietic stem cell transplantation for primary immunodeficiency disease [J].
Dvorak, C. C. ;
Cowan, M. J. .
BONE MARROW TRANSPLANTATION, 2008, 41 (02) :119-126
[10]   Megadose CD34+ cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation [J].
Dvorak, Christopher C. ;
Hung, Giun-Yi ;
Horn, Biljana ;
Dunn, Elizabeth ;
Oon, Ching-Ying ;
Cowan, Morton J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (10) :1125-1133